Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Total Non-current Liabilities
All obligations due after more than one year.
Citius Oncology, Inc.NASDAQ: CTOR
Total Non-current Liabilities · Q2 FY2026 · quarter ended Mar 2026
Total non-current liabilities rises 9.3% from a year ago
Total non-current liabilities stood at $6.62M at the end of Q2 FY2026, up 9.3% from a year earlier and down 3.4% from the prior quarter. Over 3 fiscal years it compounded at +125.3% a year.
Context
- Total non-current liabilities amounted to 6.6% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Total non-current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +9.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 6.59M USD
- Year-over-year change
- +19.1%
- 3-year CAGR
- +125.3%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 6.59M | +19.1% |
| FY2024 | 2024-09-30 | 5.53M | +379.9% |
| FY2023 | 2023-09-30 | 1.15M | +100.0% |
| FY2022 | 2022-09-30 | 576K | — |
Total Non-current Liabilities vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's Mar 2026 total non-current liabilities of $6.62M is the 6th highest of the 10 companies compared; the peer median is $23.85M.
- Its year-over-year change of +9.3% is the 3rd highest of 9, against a peer median of -11.1%.
- Total non-current liabilities amounts to 6.6% of total assets for CTOR, versus a peer median of 15.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $641.09M | +2317.8% | +156.8% | 126.5% | |
| Mar 2026 | $74.52M | -9.2% | -11.1% | 26.2% | |
| Mar 2026 | $71.78M | -12.9% | -33.4% | 61.0% | |
| Mar 2026 | $45.95M | +212.3% | +157.6% | 15.6% | |
| Mar 2026 | $23.85M | -64.9% | +185.7% | 36.0% | |
CTORCitius Oncology, Inc. | Mar 2026 | $6.62M | +9.3% | +125.3% | 6.6% |
| Mar 2026 | $2.77M | -87.8% | +40.5% | 3.2% | |
| Mar 2026 | $1.48M | — | — | 2.2% | |
| Mar 2026 | $598K | -95.9% | -66.4% | 1.0% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $404.99K | -2.8% | -32.3% | 4.5% |
| Peer median (excluding CTOR) | $23.85M | -11.1% | +14.7% | 15.6% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.